Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    FDA authorizes Novavax Covid vaccine targeting JN.1

    AdminBy AdminAugust 30, 2024 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    FDA authorizes Novavax Covid vaccine targeting JN.1

    A vial labelled “Novavax V COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. 

    Dado Ruvic | Reuters

    The Food and Drug Administration authorized Novavax‘s updated protein-based Covid vaccine for emergency use in people ages 12 and up on Friday, paving the way for the shot to compete with Pfizer and Moderna‘s jabs this fall and winter. 

    Novavax’s vaccine targets the highly contagious omicron subvariant JN.1, which began circulating widely in the U.S. earlier this year. JN.1 only accounted for 0.2% of cases circulating nationwide as of this week, according to the latest Centers for Disease Control and Prevention data. 

    Novavax manufactures protein-based vaccines, which cannot be quickly updated to target another strain of the virus.

    Despite that, the biotech company has noted that its shot provides protection against descendants of JN.1 that are currently dominant in the U.S., including KP.2.3, KP.3, KP.3.1.1 and LB.1.

    “Our updated vaccine targets JN.1, the ‘parent strain’ of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses,” Novavax CEO John Jacobs said in a statement.

    Novavax said it expects its shot to be “broadly available” in thousands of locations across the U.S., including retail and independent pharmacies and regional grocers.

    Shares of Novavax rose more than 8% on Friday following the announcement. 

    The FDA’s decision comes only a week after it approved a new round of messenger RNA shots from Pfizer and Moderna, which both target another offshoot of JN.1 called KP.2. Last year, the agency authorized Novavax’s shot nearly a month after clearing vaccines from its rivals, putting the company at a disadvantage. 

    Public health officials see Novavax’s vaccine as a valuable alternative for people who don’t want to take mRNA shots from Pfizer and Moderna, which use a newer vaccine method to teach cells how to make proteins that trigger an immune response against Covid. Novavax’s shot, meanwhile, fends off the virus with protein-based technology, a decades-old method used in routine vaccinations against hepatitis B and shingles.

    It’s unclear how many people will get a new Covid shot this fall and winter. 

    Only around 22.5% of U.S. adults received the latest round of shots that came out last fall, according to CDC data through early May. 

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Anthropic prices IPO at $83 a share, blowing past target range: report

    November 19, 2026

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    November 18, 2026

    Chipotle launches Sneak It In hoodies with hidden pouch to keep your burrito warm

    November 17, 2026

    Big-ticket holiday items may be harder to find as shipping costs rise

    November 16, 2026

    Jensen Huang weighs Nvidia CEO comeback as ally plans war room: report

    November 16, 2026

    New Orleans port seeks tanker seizure after cruise ship crash sparks $1M lawsuit

    November 15, 2026
    Popular Posts

    How to tell a cyberattack from a plain old outage

    Movie Review: Elsinore

    Interview with Aletheia von Gottlieb, Author of Love Off the Ice (Sweet Snowfall Kisses Book 1) – NewInBooks

    What Were Wearing: Friendsgiving

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    Book Riots Deals of the Day for November 18, 2026

    Categories
    • Books (2,457)
    • Business (3,449)
    • Events (34)
    • Film (1,062)
    • LifeStyle (2,922)
    • Music (2,796)
    • Politics (2,355)
    • Science (1,952)
    • Technology (1,817)
    • Television (3,628)
    • US News (3,294)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Huckberry’s Sale Section Just Got BetterHuckberry’s Sale Section Just Got Better
    • Inflation ETF may be in a sweet spot even if Fed cuts ratesInflation ETF may be in a sweet spot even if Fed cuts rates
    • How To Detect Fake Seiko WatchesHow To Detect Fake Seiko Watches
    • Premiere Date, Cast, Plot, and MorePremiere Date, Cast, Plot, and More
    • Apple Investors More Interested in AI Announcements Than Apple Reality Pro Headset at WWDC: Ming-Chi Kuo
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.